Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hoth Therapeutics ( (HOTH) ) has shared an announcement.
On June 18, 2025, Hoth Therapeutics announced it regained compliance with Nasdaq’s minimum bid price requirement, a significant milestone that reflects growing market confidence in its strategy and pipeline. This achievement allows Hoth to focus on advancing its clinical portfolio across multiple therapeutic areas, positioning the company for significant value creation in 2025.
The most recent analyst rating on (HOTH) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.
More about Hoth Therapeutics
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. Their pipeline includes treatments targeting rare diseases, inflammatory skin disorders, cancer, and neurological conditions.
Average Trading Volume: 1,168,950
Technical Sentiment Signal: Buy
Current Market Cap: $17.7M
Find detailed analytics on HOTH stock on TipRanks’ Stock Analysis page.